June 7, 2016
Meiogenix and Lesaffre enter into a collaboration agreement to develop improved industrial yeast strains using Meiogenix’s recombination technologies. The PhoeniX technology developed by Meiogenix controls the process of natural meiotic recombination and generates efficiently non–GM recombined yeast cells particularly for industrial strains where meiosis is impeded.
Meiogenix and Cambridge University receive a BBSRC grant to unlock plant genetic diversity via epigenetic modifications
April 26, 2016
Meiogenix and the group lead by Ian Henderson at the University of Cambridge have received a grant from the Biotechnology and Biological Sciences Research Council (BBRSC), UK. This grant funds research that aims at elucidating the epigenetic mechanisms that control meiotic recombination. The final goal is to apply these discoveries in crops such as wheat to recombine their natural genetic diversity and to accelerate plant breeding.
April 6, 2016
Meiogenix, a biotech company that develops breeding technologies to unlock the unexplored genetic diversity of organisms, announced today it has signed a collaboration agreement with Bayer’s Crop Science division to apply SpiX technology in crops.
March 21, 2012
Meiogenix, a genomic biotech company developing a technology that modulates meiotic recombination (SpiX), has announced the constitution of its Scientific Advisory Board. Dr. Alain Nicolas will chair the SAB, and is joined by Prof. Holger Puchta and Prof. Philip Avner.
January 28, 2011
Meiogenix and CIRAD signed a collaboration agreement to evaluate the impact of Meiogenix’s SpiX® technology in modulating meiotic homologous recombination in the genome of rice. The research program which will be performed in the laboratory of Dr. Emmanuel Guiderdoni, an expert in rice genomics, could lead to the identification of new natural varieties of rice with high commercial potential.
January 8, 2011
Meiogenix SAS, a French start-up biotech company developing a new genomic technology, closed its first round of financing of 1,2M€ from Kurma Biofund, a French venture capital fund focused in Life Sciences.